Adverse events (treatment related) To discharge · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (treatment related) To discharge · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (treatment related) To discharge · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (treatment related) To discharge · newborn infants with opioid withdrawal
1 finding from 1 review
Adverse events (treatment related) To discharge · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma‐related non‐fatal serious adverse events · children with chronic asthma
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Adverse events (all adverse events) at 26 weeks · vascular dementia and other vascular cognitive impairments
Galantamine probably leads to higher adverse events (all adverse events) at 26 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (all adverse events) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).
1 finding from 1 review
Adverse events: minor gastrointestinal symptoms · healthy people and healthy male physicians
Vitamin A leads to higher adverse events: minor gastrointestinal symptoms compared with placebo (high certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse events attributable to treatment · children with SMA type I
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children and adolescents with chronic asthma
It is very uncertain whether regular formoterol and ICS changes asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (very low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Withdrawals due to adverse events · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors may leads to higher tolerability (withdrawal due to adverse events) compared with placebo (low certainty).
1 finding from 1 review
Numbers of children with serious adverse events · children with egg allergy
1 finding from 1 review